Cover Image
Market Research Report

Global Anti-Obesity Drugs Market Forecast 2018-2028

Published by Visiongain Ltd Product code 178609
Published Content info 250 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Anti-Obesity Drugs Market Forecast 2018-2028
Published: November 20, 2018 Content info: 250 Pages
Description

Title:
GLOBAL ANTI-OBESITY DRUGS MARKET FORECAST 2018-2028
Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.

The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 119 tables and 139 figures- all unavailable elsewhere.

The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Anti-obesity Drugs Market forecast from 2018-2028

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:

  • Incretion mimetics/GLP-1 agonists
  • SNDRIs
  • Lipase Inhibitors
  • Serotonin receptor agonists
  • Sympathomimetic-GABA receptor agonists
  • Sympathomimetics

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:

  • Long-term Drugs
  • Short-term Drugs

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:

  • Innovator
  • Generic Drugs

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:

  • Prescription Drugs
  • OTC

This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:

  • Saxenda
  • Contrave/Mysimba
  • Belviq
  • Qysmia
  • Xenical
  • Alli

This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:

  • US
  • Japan
  • EU5: Germany, France, Spain, Italy, UK
  • BRIC: Brazil, Russia, China, India
  • RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:

  • Eisai/Arena
  • GlaxoSmithKline (GSK)
  • Novo Nordisk
  • Orexigen/Takeda
  • Roche
  • Teva
  • Vivus

This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

This report gives an overview of pricing and reimbursement in the US and EU.

This report provides a SWOT Analysis of the global anti-obesity drugs market.

Visiongain's study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Buy our report today Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents
Product Code: PHA0343

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Key Questions Answered by This Analytical Report:
  • 1.4. Who is This Report for?
  • 1.5. Methodology
    • 1.5.1. Primary Research
    • 1.5.2. Secondary Research
    • 1.5.3. Market Evaluation & Forecasting Methodology
  • 1.6. Frequently Asked Questions
  • 1.7. Associated Reports
  • 1.8. About Visiongain

2. Introduction to Obesity

  • 2.1. What is Obesity?
    • 2.1.1. Types of obesity
      • 2.1.1.1. Central Obesity / Android Type
      • 2.1.1.2. Peripheral Obesity/ Gynoid Type
  • 2.2. What are the causes and risk factors of obesity?
    • 2.2.1. Energy Imbalance
    • 2.2.2. Genetic Predisposition
    • 2.2.3. Unhealthy Diet
    • 2.2.4. Health Conditions and Medicines
    • 2.2.5. Emotional Factors
    • 2.2.6. Age
    • 2.2.7. Pregnancy
    • 2.2.8. Lack of Sleep
    • 2.2.9. Smoking
  • 2.3. Obesity Measurement
    • 2.3.1. BMI
    • 2.3.2. Waist circumference
    • 2.3.3. Index of Central Obesity
    • 2.3.4. Bioelectrical Impedance Analysis
    • 2.3.5. New Approaches/Techniques
  • 2.4. Epidemiology of Obesity
    • 2.4.1. Epidemiology by Geography
    • 2.4.2. Epidemiology by Country
    • 2.4.3. Historical Prevalence in Major Markets
    • 2.4.4. Forecast of Obesity Prevalence in Major Markets
  • 2.5. Humanistic and Economic Burden
    • 2.5.1. Mortality
    • 2.5.2. Morbidity
      • 2.5.2.1. Disability-adjusted life year (DALY)
      • 2.5.2.2. Years Lost due to Disability (YLD)
      • 2.5.2.3. Years of Life Lost (YLL)
    • 2.5.3. Economic Impact
  • 2.6. Obesity: Prevention and Treatment
    • 2.6.1. Lifestyle changes
    • 2.6.2. Pharmacotherapy
    • 2.6.3. Other treatments

3. Introduction to the Global Anti-obesity Drugs Market

  • 3.1. Market Structure
  • 3.2. Market Definition and Scope
  • 3.3. Classification by Mechanism of Action
    • 3.3.1. Incretin Mimetics/GLP-1 Agonists
    • 3.3.2. Lipase Inhibitors
    • 3.3.3. Serotonin-norepinephrine-dopamine Reuptake (SNDRI) Inhibitors
    • 3.3.4. Serotonin Receptor Agonists
    • 3.3.5. Sympathomimetics
    • 3.3.6. Sympathomimetic-GABA Receptor Agonists
    • 3.3.7. Others
  • 3.4. Classification by Innovator or Generics Drugs
    • 3.4.1. Innovator Drugs
    • 3.4.2. Generics Drugs
  • 3.5. Classification by Prescription or OTC drugs
    • 3.5.1. Prescription drugs
    • 3.5.2. OTC drugs
  • 3.6. Classification by Duration of Therapy
    • 3.6.1. Short-term drugs
    • 3.6.2. Long-term drugs

4. Global Anti-obesity Drugs Market 2018-2028

  • 4.1. Global Anti-obesity Drugs Market 2017
  • 4.2. Global Anti-obesity Drugs Market Forecast 2017-2028
  • 4.3. Global Anti-obesity Drugs by Mechanism of Action
    • 4.3.1. Global Anti-obesity Drugs by Mechanism of Action: Market Forecasts 2018-2028
      • 4.3.1.1. Incretin mimetics/GLP-1 Agonists: Market Forecasts 2018-2028
      • 4.3.1.2. Lipase Inhibitors: Market Forecasts 2018-2028
      • 4.3.1.3. Serotonin-norepinephrine-dopamine Reuptake Inhibitors (SNDRI): Market Forecasts 2018-2028
    • 4.3.2. Serotonin Receptor Agonists: Market Forecasts 2018-2028
      • 4.3.2.1. Sympathomimetic-GABA Receptor Agonists: Market Forecasts 2018-2028
      • 4.3.2.2. Sympathomimetics: Market Forecasts 2018-2028
      • 4.3.2.3. Others: Market Forecasts 2018-2028
    • 4.3.3. Global Anti-obesity Drugs Market Forecasts by Mechanism of Action: Market Share 2018-2028
  • 4.4. Global Anti-obesity Drugs Market by Innovator and Generics Drugs
    • 4.4.1. Global Anti-obesity Drugs by Innovator Drugs and Generics: Market Forecasts 2018-2028
      • 4.4.1.1. Innovator Drugs: Market Forecasts 2018-2028
      • 4.4.1.2. Generics: Market Forecasts 2018-2028
    • 4.4.2. Global Anti-obesity Drugs Market Forecast by Innovator Drugs and Generics: Market Share 2018-2028
  • 4.5. Global Anti-obesity Drugs Market by Prescription and OTC Drugs
    • 4.5.1. Global Anti-obesity Drugs Market by Prescription and OTF Drugs: Market Forecast 2018-2028
      • 4.5.1.1. Prescription Drugs: Market Forecasts 2018-2028
      • 4.5.1.2. OTC Drugs: Market Forecasts 2018-2028
    • 4.5.2. Global Anti-obesity Drugs Market Forecast by Prescription and OTC Drugs: Market Share 2018-2028
  • 4.6. 4.6. Global Anti-obesity Drugs Market by Duration of Therapy
    • 4.6.1. Global Anti-obesity Drugs Market by Duration of Therapy: Market Forecast 2017-2028
      • 4.6.1.1. Short-term Anti-obesity Drugs: Market Forecasts 2018-2028
      • 4.6.1.2. Long-term Anti-obesity Drugs: Market Forecasts 2018-2028
    • 4.6.2. Global Anti-obesity Drugs Market Forecast by Duration of Therapy: Market Share 2017-2028
  • 4.7. Overall Global Anti-obesity Drugs Market Drivers, Restraints and Trends

5. Leading Anti-obesity Drugs

  • 5.1. Snapshot of Anti-obesity Drugs
  • 5.2. Innovator Drugs
    • 5.2.1. Saxenda
      • 5.2.1.1. Saxenda Drug Profile
      • 5.2.1.2. Saxenda Historical Sales
      • 5.2.1.3. Saxenda Forecast 2018-2028
      • 5.2.1.4. Saxenda Sales by Geography, 2017
    • 5.2.2. Contrave / Mysimba
      • 5.2.2.1. Contrave Drug Profile
      • 5.2.2.2. Contrave Historical Sales
      • 5.2.2.3. Contrave Forecast 2018-2028
      • 5.2.2.4. Contrave Sales by Geography, 2017
    • 5.2.3. Belviq
      • 5.2.3.1. Belviq Drug Profile
      • 5.2.3.2. Belviq Historical Sales
      • 5.2.3.3. Belviq Forecast 2018-2028
      • 5.2.3.4. Belviq Sales by Geography, 2017
    • 5.2.4. Qysmia
      • 5.2.4.1. Qysmia Drug Profile
      • 5.2.4.2. Qysmia Historical Sales
      • 5.2.4.3. Qysmia Forecast 2018-2028
      • 5.2.4.4. Qysmia Sales by Geography, 2017
    • 5.2.5. Xenical and Alli
      • 5.2.5.1. Xenical and Alli Historical Sales
      • 5.2.5.2. Xenical and Alli Sales by Geography, 2017
      • 5.2.5.3. Xenical and Alli Forecast 2018-2028
    • 5.2.6. Cametor/Oblean
    • 5.2.7. Lomaira
  • 5.3. Generics
    • 5.3.1. Orlistat
      • 5.3.1.1. Orlistat Historical Sales
    • 5.3.2. Sibutramine
      • 5.3.2.1. Sibutramine Historical Sales
    • 5.3.3. Adipex
      • 5.3.3.1. Adipex Historical Sales
    • 5.3.4. Phentermine
      • 5.3.4.1. Phentermine Historical Sales

6. Leading National Markets Forecast 2018-2028

  • 6.1. Geographical Breakdown of Global Anti-obesity Drugs Market, 2017
    • 6.1.1. Regional Breakdown of Global Anti-obesity Drugs Market, 2017
    • 6.1.2. Country Breakdown of Global Anti-obesity Drugs Market, 2017
  • 6.2. Regional Forecast of Global Anti-obesity Drugs Market, 2018-2028
  • 6.3. US Anti-obesity Drugs Market
    • 6.3.1. US Anti-obesity Drugs: Market Forecasts 2018-2028
  • 6.4. Japan Anti-obesity Drugs Market
    • 6.4.1. Japan Anti-obesity Drugs: Market Forecasts 2018-2028
  • 6.5. EU5 Anti-obesity Drugs Market, 2017
    • 6.5.1. EU5 Anti-obesity Drugs: Market Forecast 2018-2028
      • 6.5.1.1. The UK Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.5.1.2. Germany Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.5.1.3. France Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.5.1.4. Italy Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.5.1.5. Spain Anti-obesity Drugs: Market Forecasts 2018-2028
  • 6.6. BRIC Anti-obesity Drugs Market, 2017
    • 6.6.1. BRIC Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.6.1.1. China Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.6.1.2. India Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.6.1.3. Brazil Anti-obesity Drugs: Market Forecasts 2018-2028
      • 6.6.1.4. Russia Anti-obesity Drugs: Market Forecasts 2018-2028

7. Research and Development for Treating Obesity

  • 7.1. Novel Mechanism of Action of Pipeline Drugs
  • 7.2. Active Pipeline Molecules
  • 7.3. Promising Potential Pipeline Molecules
    • 7.3.1. Phase III Molecules
      • 7.3.1.1. BTI-320
    • 7.3.2. Phase II Molecules
      • 7.3.2.1. Oxyntolong
      • 7.3.2.2. Antisense FGFR4 oligo, Verva
      • 7.3.2.3. S-237648
      • 7.3.2.4. Setmelanotide
      • 7.3.2.5. Bupropion + zonisamide SR
      • 7.3.2.6. Semaglutide
      • 7.3.2.7. LIK066
      • 7.3.2.8. Tesofensine
      • 7.3.2.9. LIPO-202
      • 7.3.2.10. Canagliflozin and Phentermine
      • 7.3.2.11. OBEP-100
      • 7.3.2.12. Efpeglenatide
      • 7.3.2.13. EMP16
      • 7.3.2.14. MEDI-0382

8. Pricing and Reimbursement Overview

  • 8.1. US
  • 8.2. EU
  • 8.3. Payers Perspective

9. Qualitative Analysis of the Global Anti-obesity Drugs Market

  • 9.1. SWOT Analysis, 2017

10. Leading Companies in Global Anti-obesity Drugs Market, 2017

  • 10.1. Novo Nordisk
    • 10.1.1. Obesity Care - To Establish its presence
  • 10.2. Orexigen/Takeda
    • 10.2.1. Collaboration Agreement with Takeda Pharmaceutical Company Limited
    • 10.2.2. Collaboration Agreement with Valeant
  • 10.3. Arena/Eisai
    • 10.3.1. Collaboration Agreement with Eisai Co., Ltd.
    • 10.3.2. Collaboration Agreement with Other Companies
  • 10.4. F. Hoffmann-La Roche Ltd.
  • 10.5. Vivus
  • 10.6. Teva
  • 10.7. GlaxoSmithKline (GSK)

11. Conclusions

  • Associated visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: WHO BMI Cut Off Points
  • Table 2.2: Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk
  • Table 3.1: Mechanism of Action of Innovator Drugs for the treatment of Obesity
  • Table 3.2: List of Innovator Drugs for the treatment of Obesity
  • Table 3.3: List of Prescription Drugs for the treatment of Obesity
  • Table 3.4: Long-term Prescription Drugs for the treatment of Obesity
  • Table 4.1: Global Anti-obesity Drugs Market by Markets: Revenue ($m), and Market Share (%), 2017
  • Table 4.2: Global Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.3: Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4: Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%)
  • Table 4.5: Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.6: List of Active GLP-1 agonists in Clinical Pipeline
  • Table 4.7: Global Anti-obesity Lipase Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.8: List of Active SNDRI agonists in Clinical Pipeline
  • Table 4.9: Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.10: Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.11: Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.12: Global Anti-obesity Sympathomimetic Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.13: Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.14: Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Market Share (%)
  • Table 4.15: Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.16: Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2017-2028: AGR (%)
  • Table 4.17: Global Anti-obesity Innovator Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.18: Global Anti-obesity Generic Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.19: Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Market Share (%)
  • Table 4.20: Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.21: Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: AGR (%)
  • Table 4.22: Global Anti-obesity Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.23: Global Anti-obesity OTC Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.24: Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Market Share (%)
  • Table 4.25: Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.26: Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: AGR (%)
  • Table 4.27: Global Anti-obesity Short-term Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.28: Global Anti-obesity Long-term Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.1: Saxenda Drug Profile
  • Table 5.2: Saxenda Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.3: Contrave Drug Profile
  • Table 5.4: Contrave Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.5: Belviq Drug Profile
  • Table 5.6: Belviq Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.7: Qysmia Drug Profile
  • Table 5.8: Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.9: Alli Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.1: Global Anti-obesity Drugs Market by Region: Revenue ($m), and Market Share (%), 2017
  • Table 6.2: Global Anti-obesity Drugs Market by Country: Revenue ($m), and Market Share (%), 2017
  • Table 6.3: Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.4: Global Anti-obesity Drugs Market by Region: AGR 2017-2028 (%)
  • Table 6.5: Global Anti-obesity Drugs Market by Region: Market Share (%), 2017-2028
  • Table 6.6: US Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.7: U.S. Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.8: U.S. Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.9: US Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.10: US Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.11: Japan Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.12: Japan Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.13: Japan Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.14: Japan Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.15: Japan Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.16: EU5 Anti-obesity Drugs Market by Region: Market Size ($m) and Share (%), 2017
  • Table 6.17: EU5 Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.18: EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2017-2028 (%)
  • Table 6.19: EU5 Anti-obesity Drugs Market Forecast by Region: AGR (%) 2017-2028
  • Table 6.20: UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.21: UK Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.22: UK Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.23: UK Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.24: UK Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.25: Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.26: Germany Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.27: Germany Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.28: Germany Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.29: Germany Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.30: France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.31: France Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.32: France Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.33: France Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.34: France Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.35: Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.36: Italy Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.37: Italy Anti-obesity Drugs Market Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.38: Italy Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.39: Italy Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.40: Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.41: Spain Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.42: Spain Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.43: Spain Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.44: Spain Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.45: Anti-obesity Drugs Market in the BRIC Region: Market Size ($m) & Share 2017 (%)
  • Table 6.46: BRIC Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.47: China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.48: China Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.49: China Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.50: China Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.51: China Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.52: India Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.53: India Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.54: India Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.55: India Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.56: India Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.57: Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.58: Brazil Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.59: Brazil Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.60: Brazil Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.61: Brazil Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.62: Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.63: Russia Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.64: Russia Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.65: Russia Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.66: Russia Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.1: Active Pipeline Molecules under Development for Treating Obesity
  • Table 10.1: Innovator Drugs' Originator-Licensee Information
  • Table 10.2: Novo Nordisk A/S: Overview
  • Table 10.3: Novo Nordisk: List of Active Clinical Pipeline Molecules
  • Table 10.4: Orexigen: Overview
  • Table 10.5: Arena: Overview
  • Table 10.6: Roche: Overview
  • Table 10.7: Vivus: Overview
  • Table 10.8: Teva: Overview
  • Table 10.9: Vivus: Overview

List of Figures

  • Figure 2.1: Prevalence of Obesity by WHO region, ages 18+, Both sexes, 2014
  • Figure 2.2: Prevalence of Overweight, ages 18+, 2010-2014, age standardized estimate: Both sexes 2014
  • Figure 2.3: Prevalence of Obesity, ages 18+, 2010-2014, age standardized estimate: Both sexes 2014
  • Figure 2.4: Prevalence of Obesity in OECD 32 Countries - population aged 15 years and over, 2013 or nearest year
  • Figure 2.5: Prevalence of Obesity in G7 and BRIC Countries - population aged 15 years and over, 2012 or nearest year, men, women, both sexes
  • Figure 2.6: Age-Standardized Obesity Prevalence Rate in Major Markets - Population aged 15 years and over, 1973-2012
  • Figure 2.7: Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2017-2028, million, CAGR% (2017-2028)
  • Figure 2.8: Deaths due to Obesity in G7 and BRIC Nation: Absolute Number (000's), 2015
  • Figure 2.9: DALY's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 2.10: YLD's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 2.11: YLL's due to Obesity in G7 and BRIC Nation: Absolute Number (000's), 2015
  • Figure 3.1: Global Anti-obesity Drugs Market Segmentation Overview
  • Figure 3.2: Anti-Obesity Drugs Classification by Mechanism of Action, 2017
  • Figure 4.1: Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2017
  • Figure 4.2: Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2017
  • Figure 4.3: Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017
  • Figure 4.4: Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017
  • Figure 4.5: Global Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.6: Global Anti-obesity Drugs Market by Mechanism of Action 2017, Revenue ($m)
  • Figure 4.7: Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2017
  • Figure 4.8: Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: Revenue ($m), Global AGR (%)
  • Figure 4.9: Global Anti-obesity Drugs Market by Mechanism of Action 2017 and 2028: Revenue ($m), CAGR (%) 2017-2028
  • Figure 4.10: Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%)
  • Figure 4.11: Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.12: Global Anti-obesity Lipase Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.13: Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.14: Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.15: Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.16: Global Anti-obesity Sympathomimetic Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.17: Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.18: Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2017-2028: Market Share (%)
  • Figure 4.19: Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2022
  • Figure 4.20: Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2028
  • Figure 4.21: Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue ($m), 2017
  • Figure 4.22: Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2017
  • Figure 4.23: Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Revenue ($m), Global AGR (%)
  • Figure 4.24: Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%)
  • Figure 4.25: Global Anti-obesity Drugs Market by Mechanism of Action 2017-2028: AGR (%)
  • Figure 4.26: Global Anti-obesity Innovator Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.27: Global Anti-obesity Generic Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.28: Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2017-2028: Market Share (%)
  • Figure 4.29: Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2022
  • Figure 4.30: Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2028
  • Figure 4.31: Global Anti-obesity Drugs Market by Prescription and OTC Drugs, Revenue 2017 ($m)
  • Figure 4.32: Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017
  • Figure 4.33: Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Revenue ($m), Global AGR (%)
  • Figure 4.34: Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%)
  • Figure 4.35: Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: AGR (%)
  • Figure 4.36: Global Anti-obesity Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.37: Global Anti-obesity OTC Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.38: Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2017-2028: Market Share (%)
  • Figure 4.39: Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2017
  • Figure 4.40: Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2028
  • Figure 4.41: Global Anti-obesity Drugs Market by Duration of Therapy: Revenue ($m), 2017
  • Figure 4.42: Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017
  • Figure 4.43: Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.44: Global Anti-obesity Drugs Market by Duration of Therapy: Revenue 2017 and 2028 ($m), CAGR 2017-2028 (%)
  • Figure 4.45: Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: AGR (%)
  • Figure 4.46: Global Anti-obesity Short-term Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.47: Global Anti-obesity Long-term Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.48: Global Anti-obesity Drugs Market by Duration of Therapy 2017-2028: Market Share (%)
  • Figure 4.49: Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2017
  • Figure 4.50: Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2028
  • Figure 4.51: Global Anti-obesity Drugs Market: Drivers and Restraints
  • Figure 4.52: Trends in Global Anti-obesity Drugs Market
  • Figure 5.1: Leading Anti-obesity Drug Sales, Revenue ($m), 2017
  • Figure 5.2: Leading Anti-obesity Drug Sales, Market Share (%), 2017
  • Figure 5.3: Anti-obesity Drugs Sales Forecast, Market Share (%), 2028
  • Figure 5.4: Leading Anti-obesity Drugs: Historical Revenue ($m), 2012-2017
  • Figure 5.5: Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2017
  • Figure 5.6: Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2028
  • Figure 5.7: Saxenda Global Sales: Revenue ($million), 2015-2016
  • Figure 5.8: Saxenda Sales Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 5.9: Saxenda Sales by Geography: Market Share (%), 2017
  • Figure 5.10: Contrave Global Sales: Revenue ($million), 2014-2016
  • Figure 5.11: Contrave Sales Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 5.12: Contrave Sales by Geography: Market Share (%), 2017
  • Figure 5.13: Belviq Global Sales: Revenue ($million), 2013-2016
  • Figure 5.14: Belviq Sales Forecast 2017-2028: Revenue ($million), AGR (%)
  • Figure 5.15: Belviq Sales by Geography: Market Share (%), 2017
  • Figure 5.16: Qysmia Global Sales: Revenue ($m), 2013-2016
  • Figure 5.17: Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 5.18: Qysmia Sales by Geography: Market Share (%), 2017
  • Figure 5.19: Xenical Global Sales: Revenue ($million), 2011-2016
  • Figure 5.20: Alli Global Sales: Revenue ($million), 2011-2016
  • Figure 5.21: Xenical Sales by Geography: Market Share (%), 2017
  • Figure 5.22: Alli Sales by Geography: Market Share (%), 2017
  • Figure 5.23: Alli Sales Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 5.24: Global Anti-obesity Generics Market by Individual Compound: Market Share (%), 2017
  • Figure 5.25: Orlistat Global Sales: Revenue ($m), 2011-2016
  • Figure 5.26: Sibutramine Global Sales: Revenue ($m), 2012-2017
  • Figure 5.27: Adipex Global Sales: Revenue ($m), 2012-2017
  • Figure 5.28: Phentermine Global Sales: Revenue ($m), 2012-2017
  • Figure 6.1: Global Anti-obesity Drugs Market Segmentation by Region/Country
  • Figure 6.2: Global Anti-obesity Drugs Market by Region: Revenue ($m), 2017
  • Figure 6.3: Global Anti-obesity Drugs Market by Region: Market Share (%), 2017
  • Figure 6.4: Global Anti-obesity Drugs Market by Country: Revenue ($m), 2017
  • Figure 6.5: Global Anti-obesity Drugs Market by Country: Market Share (%), 2028
  • Figure 6.6: Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2017-2028
  • Figure 6.7: Global Anti-obesity Drugs Market Forecast by Region 2017, 2022, 2028: Revenue ($m), CAGR 2017-2028 (%)
  • Figure 6.8: Global Anti-obesity Drugs Market by Region: AGR 2017-2028 (%)
  • Figure 6.9: Global Anti-obesity Drugs Market by Region: Market Share (%), 2017-2028
  • Figure 6.10: Global Anti-obesity Drugs Market by Region: Market Share (%), 2017
  • Figure 6.11: Global Anti-obesity Drugs Market by Region: Market Share (%), 2022
  • Figure 6.12: Global Anti-obesity Drugs Market by Region: Market Share (%), 2028
  • Figure 6.13: US Anti-obesity Drugs Market by Mechanism of Action: Market Share %, 2017
  • Figure 6.14: US Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 6.15: Japan Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 6.16: EU5 Anti-obesity Drugs Market by Region: Global Market Share (%), 2017
  • Figure 6.17: EU5 Anti-obesity Drugs Market by Region: Market Share (%), 2017
  • Figure 6.18: EU5 Anti-obesity Drugs Market Forecast by Region 2017-2028: Revenue ($m), AGR (%)
  • Figure 6.19: EU5 Anti-obesity Drugs Market by Region 2017 and 2028: Revenue ($m), CAGR 2017-2028 (%)
  • Figure 6.20: EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2017-2028 (%)
  • Figure 6.21: EU5 Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028
  • Figure 6.22: EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2023
  • Figure 6.23: EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2028
  • Figure 6.24: EU5 Global Anti-obesity Drugs Market Forecast by Region: AGR (%), 2017-2028
  • Figure 6.25: UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.26: Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.27: France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.28: Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.29: Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.30: BRIC Anti-obesity Drugs Market by Region: Global Market Share 2017 (%)
  • Figure 6.31: BRIC Anti-obesity Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 6.32: BRIC Anti-obesity Drugs Market Forecast 2017 and 2028: Revenue ($m), CAGR 2017-2028 (%)
  • Figure 6.33: BRIC Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028
  • Figure 6.34: BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2017
  • Figure 6.35: BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2028
  • Figure 6.36: China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.37: India Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028
  • Figure 6.38: Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028
  • Figure 6.39: Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2017-2028
  • Figure 7.1: Anti-obesity Clinical Pipeline Segmentation by Phase, 2017
  • Figure 7.2: Anti-obesity Pipeline Segmentation by Mechanism of Action, 2017
  • Figure 9.1: SWOT Analysis of the Global Anti-obesity Drugs Market
  • Figure 10.1: Global Anti-obesity Drugs Market by Company: Revenue ($m)
  • Figure 10.2: Global Anti-obesity Drugs Market by Company 2017: Market Share (%)
  • Figure 10.3: Novo Nordisk's 20-year R&D journey in Obesity - Milestones of Saxenda
  • Figure 11.1: Global Anti-obesity Drugs Market by Region: Share (%), 2017 and 2028

COMPANIES LISTED:

  • ADial Pharmaceuticals
  • AEMPS
  • AIFA
  • HAS
  • Akrimax Pharmaceuticals
  • American Medical Association
  • Arena Pharmaceuticals
  • AstraZeneca
  • Biophytis
  • Boehringer Ingelheim
  • Boston Therapeutics
  • Diasome
  • Eisai
  • EMEA
  • Empros Pharma
  • FDA
  • G-BA
  • GenePreDiT
  • GlaxoSmithKline (GSK)
  • Hanmi
  • Ildong Pharmaceuticals
  • Intarcia Therapeutics
  • Ionis Pharmaceuticals
  • Janssen Pharmaceuticals
  • KT&G Life Sciences
  • KVK Tech
  • Kwang Dong
  • Medivation
  • Medlab Clinical
  • Neothetics
  • NGM Biopharmaceuticals
  • NICE
  • SMC
  • Novartis
  • Novo Nordisk
  • OPKO Health
  • Orexigen
  • Rhythm Pharmaceuticals
  • Roche
  • Saniona
  • Shionogi & Co., Ltd
  • Takeda
  • Teva
  • Valeant Pharmaceuticals
  • Virtici
  • Vivus
  • World Health Organization (WHO)
  • Xenetic Biosciences
  • Zafgen
Back to Top